Uncategorized

The Quick Version Three months ago, you were facing a cash flow gap that risked slowing your product roadmap. Your R&D Tax Incentive refund was still months away, while eligible spend continued to build. So you did the smart thing: you took out an R&D loan against that accrued expenditure and put the capital straight … Read more

Five themes every R&D-active business should be watching When Cooperative Research Australia brings together researchers, policymakers, and industry leaders at The University Club of Western Australia this May for Collaborate & Innovate 2026, the conversation won’t be about whether Australia can innovate. That question was settled years ago. The real conversation is about what happens … Read more

The Quick Version You’ve spent $2 million on R&D this financial year. Your R&D Tax Incentive claim will return $870,000 at the refundable offset (your 25% company tax rate plus the 18.5% R&D premium, totalling 43.5% for most eligible companies under $20M turnover), and that number is probably sitting in your financial model right now, … Read more

You’ve just closed a quarter where your engineering team shipped three major features, refactored your authentication system, and started building a new customer portal. Your finance lead asks: “Which of these costs should we capitalise?” The question sounds simple. However, the answer reshapes your balance sheet, influences investor conversations, and determines how much you’ll claim … Read more

When UK quantum computing firm Quantum Motion decided where to build their next laboratory in 2024, they had the world to choose from. They picked Sydney. When Korean industrial giant POSCO wanted to establish their first Critical Minerals R&D Lab, they chose Perth. What do these global innovators know that you might be missing? Australia … Read more

For much of the last decade, Australian SMEs operated in a unique environment: A zero-interest-rate policy made capital abundant, and R&D budgets were treated as faith-based initiatives, necessary for the innovation narrative, but opaque in their financial attribution. That era has ended. With the Reserve Bank maintaining elevated cash rates and business investment expected to … Read more

Artificial intelligence is revolutionising how we approach clinical research in Australia. Today, AI systems are diagnosing leukaemia, matching lung cancer patients to appropriate clinical trials, and analysing medical imaging with remarkable accuracy. Walk into any major Australian clinical setting, and you’ll find AI tools calculating sepsis risk in emergency departments and predicting cancer outcomes.   Here’s … Read more

The IP structure you set up to protect your assets might be the exact reason the ATO denies your multi-million dollar R&D Tax Incentive claim. The ATO doesn’t just ask whether you’re doing genuine R&D. They ask: who has effective ownership of the results (including IP), who controls the R&D day-to-day, and who bears the … Read more

The constraint for most teams isn’t ambition or execution; it’s the mismatch between when costs land and when support arrives. When you turn your cost of capital into a known constant across several cycles, you take back control of timing and keep momentum. If you want funding that keeps pace with your roadmap, you’re not … Read more

Every year, thousands of Australian businesses wait for their R&D Tax Incentive (R&DTI) rebate to be processed by the ATO. While the rebate is a welcome boost, the reality is that many companies wait months after lodgement to see it, which leaves a cashflow gap right when you’re ready to hire, test, or scale. If … Read more